Study of NNC0487-0111 in people with liver disease
Treatments studied
Part of Hormones & metabolism clinical trials.
This research study tests how a new medicine (NNC0487-0111) moves through your body and how well you tolerate it. The study compares people with healthy livers to people with reduced liver function to understand if liver disease affects how the medicine works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 80 years old
- Have stable liver disease (Child-Pugh grade A, B, or C) with no recent worsening, or have a normal liver
- Not be allergic to the study medicine or similar drugs
- If female and able to become pregnant, be willing to use highly effective birth control during the study
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new experimental medicine (NNC0113-5840) to see how it works in people who are overweight or have obesity. Researchers want to understand how the body processes this medicine and whether it's safe before testing it more widely.
This study tests a new medicine (NNC6989-0001) for people who are overweight or have obesity. It checks if the medicine is safe and how the body handles it. If eligible, you would receive the study drug and be monitored closely.
This study tests a new medicine to see how well it helps people with excess body weight lose weight. It may be an option if you have tried to lose weight through dieting before but haven't had lasting success.
This study tests an investigational medicine to help people who have lost weight keep it off. It's for adults without diabetes who haven't used similar weight-loss drugs before.
This study tests an experimental drug (NNC0487-0111) to see how it changes food intake, appetite, and the way your body processes food after meals. It is for adults with obesity who do not have diabetes.
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
Hear when a new Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.